Professor of Urology
@LMU_Muenchen
, SVP Therapeutic Area Head Urologic Oncology
@AuraBiosciences
- former VP R&D
@J
&J - Sports Medicine 🚵♀️Passionate Cyclist
PSA >0.25 at time of post RP salvage therapy significantly increases all cause mortality in
#ProstateCancer
pts. Another call for early salvage treatment. Would be great to see data on PC-related death and competing risks
@Tilki_De
@felixfengmd
#D
’Amico
Great news today 👉Breakthrough Therapy Designation for TAR200🥨based on results of SunRISe-1 for potential future treatment of patients with BCG unresponsive HR-
#NMIBC
, ineligible for RC/decided not to undergo RC
#BladderCancer
#MyCompany
@JNJInnovMed
👉
Radical Cystectomy vs. Trimodality Therapy for Muscle-Invasive
#BladderCancer
. A multi-institutional analysis unveils surprising results. Bladder preservation is a compelling alternative! 📚 Read the study insights here >
#BladderHealth
@TheLancetOncol
Out now: Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
@neerajaiims
@scserendipity1
@brookmans76
@bjartell
#EMBARK
results presented by
@nealshore
at
#AUA2023
MFS significantly improved with enza/ADT vs ADT in HR
#BCR
; HR 0.42. Striking that also enza mono improved MFS vs ADT: would be interested to see whether NHT mono reduces the risk of competing risks of death as one explanation?
ERSPC Update on
#ProstateCancer
#screening
after a median 21 yrs follow-up:
➡️Metastasis + mortality reduction continue to increase
➡️Reduced prostate cancer specific mortality: RR of 0.73 (95%CI: 0.61–0.88)
➡️More favorable harm-benefit ratio over time
Please retweet and spread: In parallel to the 2nd ed. Roulons Contre Le Cancer
#ProstateCancer
Charity Event,
@BenjaminPradere
and I will be organizing a
#Roadbike
Friendship Group Ride🚴♀️🚴🚴♂️in Chicago during
#ASCO2023
. Date: June 3rd, 8 am CT, meeting point tbd, 2-3-4 hours
Excellent assessment of the role of
#LND
in
#ProstateCancer
#KidneyCancer
#UTUC
#BladderCancer
:
🔵LND = best staging method
🔵Accuracy depends on LND template
🔵Individual Risk-Benefit assessment of staging/therapeutic benefits + pt selection is key
👉
Full FDA approval for
#Erdafitinib
for the treatment of pts with locally advanced/metastatic FGFR+
#UrothelialCarcinoma
following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo
@JNJInnovMed
Great presentation of
#ARNEO
results by
@joniau
#UroOnco23
Neoadjuvant treatment apa/ADT vs ADT prior to RP in
#prostatecancer
: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR
Outcomes of 61,777/62,361 US pts with localized
#ProstateCancer
(claims/electronic health records):
✅Mostly RP (EHR) or RT (claims) as primary treatment
✅Better OS in men treated with RP
✅No Evidence of Disease (NED) at 4 yrs sign. correlated with OS (age/comorbidity adjusted)
Excellent review/MA: non-surgical interventions 5ARI, ARSI, exercise in
#ProstateCancer
#ActiveSurveillance
👉Risk of bias↗️ no reliable conclusions (yet)
👉Adding some more concerns: biopsy detection bias ➡️impact on PFS, next treatment subjectivity, possible rebound (ENACT)👇
Excellent mini review
@DrShariat
@E_Laukhtina
Next goal in
#BladderCancer
👉Bladder Preservation
Tasks to work on:
✅Reliable
#biomarker
/clinical/AI models to predict pT0 ➡️cT0 is not enough
✅Surveillance protocols
✅Adaptive study designs: induction treatment w/wo Cx
@EUplatinum
Congratulations to
@MRoupret
@AStenzl
@uroweb
for delivering this newborn
#UroOnco23
A great first event:
👉 Great speakers
👉 Excellent GU oncology coverage: new data presentation, state of the art lectures, clinical case discussions, workshops
Looking forward to
#UroOnco24
!
How can ctDNA be implemented for
#ProstateCancer
in the clinic? Great presentation by
@ResearchWyatt
➡️ Value of ctDNA as prognostic indicator with higher diversity than single metastasis/better snapshot of the tumor profile + possible treatment response
#biomarker
Happy to share convincing results from our recent MA: outcomes of RARP/LND + peritoneal interposition flap (PIF)
#ProstateCancer
👉 OR 0.46/0.51 for symptomatic/overall lymphocele, 0.41 for grade ≥3 complications
👉 no functional impairment
@EurUrolFocus
#ESMO23
#ABACUS
Trial: Neoadjuvant atezolizumab in non-urothelial
#BladderCancer
subtypes
@b_szabados
👉 Striking discrepancy btw local vs central pathology
❓Pathologists
@Markuseckstein3
- why is that? For nonUC subtypes, but also for UC grading. Can consistency be improved?
Great news today! Finally got my first
#wine
planted in
#Mallorca
Montuïri, 5,500 sqm with Monastrell + Syrah🍇🍷 Next year proceeding with white wine. And in the background of my vineyard one of my favorite hills for
#roadbike
cycling 🚵♀️, Puig de Randa, for additional motivation
Thanks to
@EurUrolOncol
for publishing our work on characterizing oncologic outcomes among patients with residual
#UTUC
following NAC and RNU in a multicenter, international cohort
What a great ride 🚴today in Chicago
#ASCO2023
! Paralleling same date as Mount Ventoux ride France - Friendship
#Roadcycling
- including some climb + steps. Next year mount Ventoux@
@BenjaminPradere
@VerhoestGregory
please share more pics! Finally finishing with a great beer🍻
Finally made it to Milano for
#EAU23
Milano. Tired after 24 hrs travel with no sleep, but re-energized by the always amazing view on the
#Alps
from Monaco di Baviera to Milano and ready for an energetic re-start with colleagues and friends
#Urology
On top of great lectures and abstracts presented at
#EAU24
+ the chance to kick off and work on
#urology
#research
projects, it was simply good to meet colleagues and friends in Paris
Great talk by
@GPloussard
Combination of systematic and targeted
#biopsy
should still be the gold standard to detect clinically significant
#ProstateCancer
and allow better prognostic and treatment counseling also due to lower rates of Gleason Score upgrading from biopsy to RP
Best of
#EAU23
session. Jochen Walz summarizing results of
#STAMPEDE
with Zoledronic Acid in mCSPC patients. Clear benefit seen in M1 with regard to bone health. Additional prophylactic measures are needed including
#exercise
🚨🚨 EV-302 data finally published
@NEJM
! Such a breakthrough for
#metastatic
#urothelial
#cancer
with doubling in OS and „insane ORR“.
👉 First
#therapy
improving OS massively by doubling overall survival of frontline metastatic patients‼️
👉 All subgroups show huge benefits‼️
Ready to be used in clinical trials + in clinical setting:
#RECIP
1.0 response evaluation criteria for
#PSMA
PET/CT
#ProstateCancer
👉 We should start getting
@RECIP_criteria
consistently implemented to generate consistent evidence with this framework
👉
RECIP 1.0 criteria determined by visual reads of nuclear medicine specialists showed 95% accuracy and excellent inter-reader agreement.
@radiology_rsna
Visual RECIP 1.0 is ready for use in daily practice and clinical trials for PCa therapy monitoring.
EMBARK study exploring enzalutamide+ADT vs ADT/placebo vs enza mono in nmCS
#ProstateCancer
and high-risk BCR met the primary endpoint MFS. Sign. difference also between Enza mono vs ADT/. Curious to see OS, subsequent treatment, PRO data
@SFreedlandMD
@nealshore
@marty_gleave
Sharing our study on disease trajectory among men with HR localized
#ProstateCancer
treated with RP or RT from the PC database Sweden
▶️10% of men overall died from PC in 10 years post diagnosis
▶️1/3 of men who received secondary ADT died from PC 10 years after ADT
@BJUIjournal
Arriving in San Antonio for
#AUA24
, the first eminent question is 👉 Do I have the right pairs of shoes 👠👞👟👢with me? Especially as a Bavarian (and
#Bavaria
is considered the Texas of Germany), living in Philly + visiting
#Texas
for the first time? Will figure it out…
Excellent talk about treatment intensification in men with metastatic hormone-sensitive
#ProstateCancer
by
@ChrisSweens1
incl. the use of living network meta-analysis for cross trial comparison to generate more evidence from existing studies and datasets
#ENZAMET
#ARASENS
👏 An inspiring session at
#SIU2023Istanbul
with our President
@lydiamakaroff
presenting WBCPC survey findings poster.
❗The poster showcases key elements of
#bladdercancer
experience with care & the importance of awareness raising and peer support.
Check out the poster👉
A week almost w/o
#urology
/
#oncology
- besides talking also about urological side effects of cycling (+positive effects as it concerns oncology) 🚴♂️🚴♂️🚴♂️ Getting
#Roadbike
training camp in
#Mallorca
started to boost me for 2023 season with a great group and guide on a great island
#TITAN
#SPARTAN
post-hoc analysis:
➡️Apa/ADT vs ADT improved OS at all ages: HR 0.57, 0.70, 0.74 (TITAN)/0.39, 0.89, 0.81 (SPARTAN) (<65, 65–79, 80+yrs)
➡️HRQoL maintained + apa well tolerated
➡️AE Variations in older pts: Side effect management should consider age + comorbidity
Just a perfect moment today to unpack pictures at my new home and find this one - my favorites
#Pel
é,
#Maradona
,
#Zidane
playing table
#football
in an obvious good mood
Interesting debate on primary RT+ADT vs ADT+ARTA with
@AttardLab
, Nicolas Mottet in
#ProstateCancer
pts low volume on conventional imaging + up to 5 PSMA-PET lesions: No level 1 evidence available to answer this question. Can Stampede results help make pragmatic decisions?
#EAU23
DFS is important in the adjuvant setting and it is great to finally see OS benefit in
#KN564
after adjuvant
#RCC
treatment, BUT:
➡️With OS not being the primary EP, informative
#censoring
+ unequal subsequent
#treatment
may impact results
👉
@TomerMeirson
How can we qualify men with GG2
#ProstateCancer
for
#ActiveSurveillance
? Great talk by
@dr_coops
at
#EAU23
outlining options to improve patient selection with clinical characteristics/CAPRA-Score -/+ additional genomic risk-classifiers (Decipher, Artera, Prolaris, Oncotype)
Excellent discussion of
#EV302
and
#CM901
studies and results + bringing all past/negative/ongoing studies with ICI in first line mUC into context
@apolo_andrea
#ESMO23
👉 Hopefully more to come for EV/Pembro combo in other
#BladderCancer
disease stages ➡️
Finally - European commission added
#ProstateCancer
to recommended
#Screening
programs. Next step: make sure we get true risk based screening well done and reduce mortality, but also over diagnosis and over treatment by proper use of risk-calculators, MRI, possibly even PSMA-PET.
#EAU23
Genetic testing is included in guidelines
@Uroweb
Do BRCA2 mutations impact clinical management of local HR disease (+/-PSMA-PET N1)? Likely not yet with regard to RP plus LND or RT plus systemic adjuvant treatment - discussion by a Pierre Blanchard, Jochen Walz
@Tilki_De
To my X community: I am searching for a Medical Director/Senior Medical Director in my R&D team at Johnson and Johnson for
#BladderCancer
. Link for application: Also reach out to me directly with any questions
This was a tough one! Rhön300
#Roadbike
Marathon - 231 km - 4530 altimeters 🚴♀️🚴🚴🚴⛰️⛰️⛰️ But great as always to start a ride in my original home village
How does 18F-rh
#PSMA
-7.3 perform in UIR/HR/VHR
#ProstateCancer
patients for detection of pelvic lymph nodes, validated by pathology?
#LIGHTHOUSE
1️⃣ High specificity in all groups 93-97%
2️⃣ Sensitivity goal not met 23-30%
3️⃣ Patient-level sensitivity ⬆️ in HR/VHR up to 53%👇
Great review on smoking, RR⬆️, lifestyle impact on
#KidneyCancer
incidence/outcomes. Proper conclusions, but I think we need to get rid of the obesity paradox👉likely a result of poor study designs and missing adjustment for earlier diagnosis, weight loss, other confounders
A really great session at
#AUA24
Thank you
#IBCG
@UroDocAsh
for an excellent agenda, great debates and speakers
#BladderCancer
Beyond others
@AStenzl
@PGrivasMDPhD
debating the need of RC in cT0 after NAC/NIO
👉biomarkers/ctDNA/MRI may help to select pts, but more evidence needed
Finally out: results of the legacy phase 1b study which built the groundwork for our ongoing phase 2 + 3 studies with the intravesical gemcitabine releasing system TAR-200 🥨
➡️TAR-200 was safe + well tolerated, with encouraging preliminary efficacy in IR
#NMIBC
@JNJInnovMed
Meta-Analysis on First-line Systemic Treatment Options for patients with metastatic hormone-sensitive
#ProstateCancer
just published in
@JAMAOnc
Great work done by
@AlanBryce9
et al.
Happy to share results from
#TITAN
(Apalutamide+ADT vs Pbo+ADT, mCSPC) with
@scserendipity1
@bjartell
, Kim Chi as lead authors: PSA decline ≥90% or to ≤0.2 ng/ml at 3 months is associated with significantly longer OS (HR 0.35), rPFS (0.44), time to PSA prog/CRPC (0.31/0.38)
#Enzamet
primary OS analysis published with 5-year OS of 57% (0·53–0·61) in control vs 67% (0·63–0·70) in enza group incl. analysis of predefined prognostic subgroups (synch/metachron/high/low-volume) + planned use of concurrent docetaxel
@ChrisSweens
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic
#UrothelialCarcinoma
from
#CheckMate
901. Presented by
@MattGalsky
.
#ASCO24
written coverage >
It is a call for action without any doubts
@UroDocAsh
More awareness needed on
#BladderCancer
and preventive measures + dedicated and targeted research. More awareness and research is also required related to the worse
#prognosis
of females compared to males
#Roadbike
fetched from Bobby’s Bike Hike and ready to go for the Friendship
#ProstateCancer
a bike ride tomorrow morning
➡️ Start at 8:30 am at Bobby’s Bike Hike 540 N Lake Shore Dr
➡️ Planned to be back right in time for the GU Poster Discussion Session at
#ASCO2023
Any chance to extend time without
#Castration
in men with
#ProstateCancer
is worth being assessed 👉MA of 22 prospective studies on metastasis directed therapy
#MTD
:
➡️ 2-yr PFS 46%
➡️ 2-yr LC, ADT-FS, OS: 97%, 55%, 97%
➡️ More data needed for OS, ideally from randomized trials
Direct treatment of metastases is a promising option for selected prostate cancer patients. It can delay hormone therapy and is being investigated as a way of intensifying treatment at the expense of manageable toxicity.
Heading back again from
#Mallorca
after a great start in the 2023
#Roadbike
season - Adiós und Hasta luego again latest in 2024 🚴♂️🚵♀️🚴♂️🚵♀️
#Cycling
After going back to Germany over the summer, just signed up for 2 of the most beautiful
#roadbike
marathons in
#Bavaria
👉
#Rh
ön300 August 5/300km/5300hm+
#ArberRadMarathon
July 30/250km/3750hm - shorter tours available as well 🚴♀️🚴♀️🚴♀️ Hope for some friends on the bike to join!
#UroOnco23
@uroweb
Seth Lerner presenting an overview on new treatments for upper tract
#UrotheliCancer
Already FDA approved
#Jelmyto
for TaLG. What comes next? Light activated endoluminal treatment
#Padeliporfin
and biodegradable drug eluding stents in development. More to come
Very low risk of
#ProstateCancer
death by age of 85 in 70–74 yr old men with prior
#PSA
#screening
➡️PCSM 0.54% in all men, 0.11% (PSA <2) 0.85% (PSA 2–3), 6.8% (PSA ≥6.5)
➡️Screening may be discontinued in men with PSA <3.0
👉
@IvodeVos
@MoniqueRoobol